Fiche publication
Date publication
septembre 2020
Journal
Current hepatology reports
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BAUMERT Thomas
,
Dr VERRIER Eloi
Tous les auteurs :
Ligat G, Goto K, Verrier E, Baumert TF
Lien Pubmed
Résumé
Chronic hepatitis B (CHB), caused by hepatitis B virus (HBV), is a major cause of advanced liver disease and hepatocellular carcinoma (HCC) worldwide. HBV replication is characterized by the synthesis of covalently closed circular (ccc) DNA which is not targeted by antiviral nucleos(t)ide analogues (NUCs) the key modality of standard of care. While HBV replication is successfully suppressed in treated patients, they remain at risk for developing HCC. While functional cure, characterized by loss of HBsAg, is the first goal of novel antiviral therapies, curative treatments eliminating cccDNA remain the ultimate goal. This review summarizes recent advances in the discovery and development of novel therapeutic strategies and their impact on cccDNA biology.
Mots clés
Antivirals, Drug discovery and development, HBV cure, Therapeutics
Référence
Curr Hepatol Rep. 2020 09;19(3):235-244
